Disease Overview：Non-Small Cell Lung Cancer（NSCLC）
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung malignancies and encompasses several histological subtypes—including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Unlike small cell lung cancer, NSCLC tends to grow and spread more slowly, offering broader therapeutic windows for localized or systemic intervention. Diagnosis relies on integrated modalities: low-dose CT screening, PET-CT staging, tissue biopsy with immunohistochemistry, and molecular profiling (e.g., EGFR, ALK, ROS1, PD-L1, KRAS, and emerging biomarkers like MET exon 14 skipping). Treatment is highly personalized—ranging from surgical resection (lobectomy or segmentectomy) and stereotactic body radiotherapy (SBRT) for early-stage disease, to targeted therapy, immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab), and platinum-based chemotherapy regimens for advanced cases.
China offers compelling advantages for NSCLC management: its top-tier oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—host internationally trained thoracic oncologists and multidisciplinary tumor boards with extensive experience in complex resections and biomarker-guided therapies. Advanced infrastructure includes PET-MRI hybrid systems, robotic-assisted thoracoscopy, and next-generation sequencing platforms validated per CAP/CLIA standards. Five-year survival rates for stage I–II NSCLC exceed 70% in high-volume centers, supported by robust real-world evidence from national registries. Crucially, treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising clinical rigor or regulatory oversight (NMPA-approved biologics and generics meet WHO-GMP standards).
As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital accreditation, coordinating pre-arrival diagnostics, arranging visa support and interpreter services, providing itemized, transparent pricing with no hidden fees, and assigning bilingual care coordinators for end-to-end clinical and logistical support—from initial consultation through follow-up telemedicine.
Non-Small Cell Lung Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Non-Small Cell Lung Cancer (NSCLC)
Non-Surgical/Medical Therapies
*Eligibility*: Stage IIIB–IV, unresectable, or medically inoperable patients; biomarker testing mandatory prior to targeted/immunotherapy.
- •Biomarker Testing (NGS panel): *EGFR*, *ALK*, *ROS1*, *BRAF*, *KRAS*, *MET*, *RET*, *NTRK*, PD-L1 IHC — $320–$480
- •EGFR-TKIs (e.g., osimertinib 80 mg/day): 1st-line *EGFR*+; monthly drug cost — $420–$680
- •ALK Inhibitors (e.g., alectinib 600 mg BID): *ALK*+; monthly drug cost — $750–$1,100
- •PD-1/PD-L1 Inhibitors (e.g., sintilimab 200 mg IV q3w): PD-L1 ≥1% or TMB-high; per infusion — $290–$410, monthly avg. $870–$1,230
- •Platinum-doublet Chemotherapy (e.g., pemetrexed + carboplatin): Biomarker-negative or ineligible for targeted/IO; per cycle (q3w) — $1,050–$1,420, includes infusion, antiemetics, hydration
- •Supportive Care Labs (CBC, LFTs, renal panel, CT chest/abdomen q3mo): $180–$260 per monitoring round
Surgical/Interventional Therapies
*Eligibility*: Clinical Stage I–IIIA, PS 0–1, adequate pulmonary reserve (FEV₁ ≥1.5 L or ≥50% predicted), no contraindications to general anesthesia.
- •Preoperative Workup: PET-CT ($480), pulmonary function tests ($85), cardiac stress test if indicated ($190), bronchoscopy with biopsy ($310)
- •Lobectomy (VATS or robotic): Standard curative-intent resection; hospital stay 5–7 days — $6,200–$9,800
- •Segmentectomy/Wedge Resection: For high-risk elderly or marginal lung function; hospital stay 4–6 days — $4,900–$7,300
- •Stereotactic Body Radiotherapy (SBRT): Medically inoperable Stage I; 3–5 fractions — $3,100–$4,600 (includes planning CT, motion management, QA)
Special/Complex Condition Management
- •Leptomeningeal Metastases: Intrathecal chemotherapy (methotrexate) + craniospinal irradiation — $8,400–$12,100 (total course)
- •Oligoprogressive Disease on TKI: Local ablation (SBRT or thermal ablation) + continued TKI — $3,800–$5,500
- •Malignant Pleural Effusion (recurrent): Indwelling pleural catheter insertion + talc pleurodesis — $2,700–$3,900
Quick Selection Guide
- •Age <70, Fit, Stage IA: VATS lobectomy ($6,200–$9,800) — highest cure rate, cost-effective long-term.
- •Age ≥75 or Severe COPD, Stage IA: SBRT ($3,100–$4,600) — non-invasive, low morbidity, comparable local control.
- •Stage IV, *EGFR*+: Osimertinib ($420–$680/month) — superior PFS, CNS penetration, outpatient-only.
- •Stage IV, PD-L1 ≥50%: Sintilimab monotherapy ($870–$1,230/month) — avoids chemo toxicity, durable responses.
- •Limited Budget (<$5,000 total): Palliative chemotherapy (carboplatin/p050/cycle) + best supportive care — balances efficacy and affordability.
- •Comorbidities renal impairment): Single-agent immunotherapy or low-dose chemo — avoids cumulative organ toxicity; pre-treatment cardiac/renal labs essential ($180–$260).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Non-Small Cell Lung Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Non-Small Cell Lung Cancer treatment with China top medical destinations:
